2025-08-25 マウントサイナイ医療システム(MSHS)
<関連情報>
- https://www.mountsinai.org/about/newsroom/2025/mount-sinai-scientists-create-ai-powered-tool-to-improve-cancer-tissue-analysis
- https://www.nature.com/articles/s41551-025-01475-9
がん組織病変における多パラメトリックな細胞および空間的組織化を簡素化されたパイプラインで解析 Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline
Mark Buckup,Igor Figueiredo,Giorgio Ioannou,Sinem Ozbey,Rafael Cabal,Alexandra Tabachnikova,Leanna Troncoso,Jessica Le Berichel,Zhen Zhao,Stephen C. Ward,Clotilde Hennequin,Guray Akturk,Steve Hamel,Maria Isabel Fiel,Rachel Brody,Myron Schwartz,Thomas U. Marron,Seunghee Kim-Schulze,Vladimir Roudko,Edgar Gonzalez-Kozlova,Pauline Hamon,Miriam Merad & Sacha Gnjatic
Nature Biomedical Engineering Published:25 August 2025
DOI:https://doi.org/10.1038/s41551-025-01475-9
Abstract
Multiplex immunostaining analysis remains fragmented, underperforming and labour intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, user-guided automated pipeline that streamlines start-to-finish, single-cell resolution analysis of whole-slide tissue, named multiplex-imaging analysis, registration, quantification and overlaying (MARQO). MARQO integrates elastic image registration, iterative nuclear segmentation, unsupervised clustering with mini-batch k-means and user-guided cell classification through a graphical interface. We compare and validate MARQO using multiplexed immunohistochemical consecutive staining on a single slide using human tumour and adjacent normal tissue samples. Performance is compared with manually curated pathologist determinations and quantification of multiple markers. We optimize MARQO to analyse diverse tissue sizes from whole tissue, biopsy, and tissue microarray and staining approaches, such as singleplex immunohistochemistry and 20-colour multiplex immunofluorescence, to determine marker co-expression patterns in multiple human solid cancer types. Lastly, we validate CD8+ T cell enrichment in hepatocellular carcinoma responders to neoadjuvant cemiplimab in a phase 2 clinical trial, further showing the ability of MARQO to identify spatially resolved in situ mechanisms by providing multiplex whole-slide single-cell resolution data.
